- Home
- GORV vs LYRA Comparison
GORV vs LYRA Comparison
Compare GORV & LYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GORV
- LYRA
- Stock Information
- Founded
- GORV 1976
- LYRA 2005
- Country
- GORV United States
- LYRA United States
- Employees
- GORV N/A
- LYRA N/A
- Industry
- GORV Retail-Auto Dealers and Gas Stations
- LYRA Medical/Dental Instruments
- Sector
- GORV Consumer Discretionary
- LYRA Health Care
- Exchange
- GORV Nasdaq
- LYRA Nasdaq
- Market Cap
- GORV 10.6M
- LYRA 11.3M
- IPO Year
- GORV 2015
- LYRA 2020
- Fundamental
- Price
- GORV $2.52
- LYRA $7.42
- Analyst Decision
- GORV
- LYRA Hold
- Analyst Count
- GORV 0
- LYRA 1
- Target Price
- GORV N/A
- LYRA $16.00
- AVG Volume (30 Days)
- GORV 1.7M
- LYRA 32.2K
- Earning Date
- GORV 11-17-2025
- LYRA 11-11-2025
- Dividend Yield
- GORV N/A
- LYRA N/A
- EPS Growth
- GORV N/A
- LYRA N/A
- EPS
- GORV N/A
- LYRA N/A
- Revenue
- GORV $662,952,000.00
- LYRA $770,000.00
- Revenue This Year
- GORV $15.65
- LYRA N/A
- Revenue Next Year
- GORV $20.54
- LYRA $123.83
- P/E Ratio
- GORV N/A
- LYRA N/A
- Revenue Growth
- GORV N/A
- LYRA N/A
- 52 Week Low
- GORV $2.04
- LYRA $3.81
- 52 Week High
- GORV $58.80
- LYRA $37.50
- Technical
- Relative Strength Index (RSI)
- GORV 46.29
- LYRA 58.23
- Support Level
- GORV $2.04
- LYRA $6.55
- Resistance Level
- GORV $3.10
- LYRA $8.75
- Average True Range (ATR)
- GORV 0.27
- LYRA 0.56
- MACD
- GORV 0.10
- LYRA 0.18
- Stochastic Oscillator
- GORV 47.17
- LYRA 52.04
About GORV Lazydays Holdings Inc.
Lazydays Holdings Inc operates recreational vehicle dealerships. It provides products and services for RV owners and outdoor enthusiasts. The company generates revenue by providing a full spectrum of RV products: New and pre-owned RV sales, RV parts and services, financing and insurance products, third-party protection plans, after-market parts and accessories, and RV camping facilities.
About LYRA Lyra Therapeutics Inc.
Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients. The Company's operations and manages its business as a single operating segment which is the business of developing targeted medicines to address ears, nose, and throat, or ENT diseases. Its initial product candidates, LYR-210 and LYR-220, are bioabsorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or CRS.